Unique Wealth LLC Has $837,000 Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Unique Wealth LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,785 shares of the company’s stock after selling 157 shares during the period. Unique Wealth LLC’s holdings in Johnson & Johnson were worth $837,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of JNJ. BCS Wealth Management acquired a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $560,000. First Financial Corp IN increased its stake in Johnson & Johnson by 15.0% during the 4th quarter. First Financial Corp IN now owns 3,135 shares of the company’s stock worth $453,000 after acquiring an additional 408 shares during the period. Signet Financial Management LLC raised its holdings in Johnson & Johnson by 11.0% in the 4th quarter. Signet Financial Management LLC now owns 17,940 shares of the company’s stock valued at $2,594,000 after acquiring an additional 1,775 shares in the last quarter. PFW Advisors LLC bought a new stake in Johnson & Johnson during the fourth quarter worth about $2,093,000. Finally, Catalyst Private Wealth LLC grew its stake in Johnson & Johnson by 6.3% during the fourth quarter. Catalyst Private Wealth LLC now owns 2,045 shares of the company’s stock worth $296,000 after buying an additional 121 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of research analyst reports. Guggenheim raised their target price on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Morgan Stanley raised their price target on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Wells Fargo & Company increased their price objective on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Finally, Royal Bank of Canada upped their price target on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a report on Wednesday, October 16th. Seven equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $174.71.

Insider Activity

In other news, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 1.7 %

Shares of NYSE:JNJ opened at $144.50 on Tuesday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The firm has a market capitalization of $347.90 billion, a P/E ratio of 20.91, a P/E/G ratio of 2.52 and a beta of 0.51. The stock has a 50 day moving average price of $149.39 and a 200-day moving average price of $156.10.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The company had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. During the same quarter in the prior year, the business posted $2.66 EPS. The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. As a group, equities research analysts anticipate that Johnson & Johnson will post 9.94 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.43%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.